ASX healthcare stocks have had a rough twelve months.
The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 37% over the past year, making it one of the worst-performing sectors on the entire ASX over that period.
The benchmark S&P/ASX 200 Index (ASX: XJO) itself is up nearly 2% over the same stretch.
That gap is extraordinary. And it has created a situation that appears, on close inspection, to be an overreaction rather than a permanent impairment.
Three names in particular are well-positioned to bounce back after a tough run.
Image source: Getty Images
CSL: The world's second-largest plasma therapies company at a 15-year low valuation
CSL Ltd (ASX: CSL) has had one of the most difficult years of any large-cap ASX healthcare stock in recent memory.
Earnings downgrades, a CEO change, and roughly $5 billion in non-cash impairments tied to the CSL Vifor acquisition have combined to send the share price down more than 50% over the past year.
Yet the business underneath those headline numbers remains the world's second-largest plasma-derived therapies company. The company benefits from barriers to entry that have taken more than a century to build and that no competitor can easily replicate.
CSL trades at approximately 14.7 times forecast FY 2026 earnings, a valuation not seen in well over a decade.
Furthermore, three company directors, including chair Carolyn Hewson and interim CEO Gordon Naylor, have bought shares on market in recent weeks. This is a strong signal that those closest to the business believe the sell-off has overshot.
Morgans retains a buy rating on CSL with a price target of $147.59, implying significant upside from current levels.
FY27 is the year the recovery either shows up or doesn't. Management itself has pointed to a new CEO and improving Behring division revenue as the specific catalysts the market should watch.
ResMed: A global sleep apnoea leader whose recovery from AI-fear selling is already underway
ResMed Inc (ASX: RMD) was sold down aggressively in 2025 on fears that GLP-1 obesity drugs would sharply reduce demand for its sleep apnoea devices.
The real-world data have not supported that fear at the scale the market priced in. ResMed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.
Sleep apnoea remains one of the most underdiagnosed conditions in the developed world.
Management estimates there are over 1 billion sufferers globally, with the vast majority still untreated.
As awareness grows and diagnosis rates improve, demand for ResMed's devices, software, and cloud-based care management tools should continue expanding well beyond any GLP-1 headwind.
ResMed's shares remain down heavily from their highs. But the recovery in underlying performance is already showing up in the numbers.
For investors who sold on fear rather than on evidence, FY27 looks more promising for this ASX healthcare stock.
Pro Medicus: AI is strengthening the moat rather than eroding it
Pro Medicus Ltd (ASX: PME) is the most counter-intuitive of the three, because the fear that drove its sell-off, that AI would displace radiology software, has been directly rebutted by the company's own actions.
Recently, Pro Medicus signed a binding agreement with EchoIQ Ltd (ASX: EIQ) to expand its AI cardiology offering. The company invested up to $20 million to acquire and resell AI-powered cardiac diagnostic technology to its existing hospital network.
That move positions Pro Medicus as the platform through which AI cardiology tools reach hospitals, rather than the platform being displaced by them.
Furthermore, Pro Medicus has demonstrated what that moat actually looks like in commercial terms.
The Allegheny Health Network contract was renewed at higher fees than before, and the Trinity Health contract runs to $330 million over ten years. As a result, five-year contracted revenue now sits at approximately $1.1 billion.
James Gerrish from Shaw and Partners has said Pro Medicus is one of the few names where AI is more likely to enhance the moat than erode it. The analyst has described the company as the most defensively positioned software business on the ASX.
Foolish Takeaway for ASX healthcare stocks
CSL, ResMed, and Pro Medicus have each been sold down for different reasons, and each has a different FY27 recovery story.
CSL's recovery depends on management delivering on the Behring margin improvement and earnings trajectory.
ResMed's recovery depends on the real-world GLP-1 data continuing to disappoint the bears.
Pro Medicus' recovery depends on investors accepting that AI is making its platform more valuable rather than less.
All three are looking quite cheap at the moment and deserve investors' attention heading into FY27.
